PALVELLA THERAPEUTICS INC (PVLA) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:PVLA • US6979471090

79.91 USD
+0.01 (+0.01%)
At close: Feb 3, 2026
79.91 USD
0 (0%)
After Hours: 2/3/2026, 8:00:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PVLA. PVLA was compared to 524 industry peers in the Biotechnology industry. While PVLA seems to be doing ok healthwise, there are quite some concerns on its profitability. PVLA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • PVLA had negative earnings in the past year.
  • In the past year PVLA has reported a negative cash flow from operations.
  • In the past 5 years PVLA always reported negative net income.
  • PVLA had a negative operating cash flow in each of the past 5 years.
PVLA Yearly Net Income VS EBIT VS OCF VS FCFPVLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -51.84%, PVLA is in line with its industry, outperforming 48.85% of the companies in the same industry.
  • The Return On Equity of PVLA (-89.05%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -51.84%
ROE -89.05%
ROIC N/A
ROA(3y)-39.21%
ROA(5y)-36.57%
ROE(3y)-79.28%
ROE(5y)-89.59%
ROIC(3y)N/A
ROIC(5y)N/A
PVLA Yearly ROA, ROE, ROICPVLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • PVLA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PVLA Yearly Profit, Operating, Gross MarginsPVLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

5

2. Health

2.1 Basic Checks

  • PVLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, PVLA has more shares outstanding
  • Compared to 5 years ago, PVLA has more shares outstanding
  • PVLA has a worse debt/assets ratio than last year.
PVLA Yearly Shares OutstandingPVLA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
PVLA Yearly Total Debt VS Total AssetsPVLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 17.32 indicates that PVLA is not in any danger for bankruptcy at the moment.
  • PVLA's Altman-Z score of 17.32 is amongst the best of the industry. PVLA outperforms 87.79% of its industry peers.
  • A Debt/Equity ratio of 0.41 indicates that PVLA is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.41, PVLA is doing worse than 69.66% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Altman-Z 17.32
ROIC/WACCN/A
WACC8.93%
PVLA Yearly LT Debt VS Equity VS FCFPVLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

  • A Current Ratio of 6.70 indicates that PVLA has no problem at all paying its short term obligations.
  • PVLA has a better Current ratio (6.70) than 68.32% of its industry peers.
  • A Quick Ratio of 6.70 indicates that PVLA has no problem at all paying its short term obligations.
  • PVLA's Quick ratio of 6.70 is fine compared to the rest of the industry. PVLA outperforms 68.51% of its industry peers.
Industry RankSector Rank
Current Ratio 6.7
Quick Ratio 6.7
PVLA Yearly Current Assets VS Current LiabilitesPVLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

  • PVLA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.54%, which is quite impressive.
  • The Revenue for PVLA has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)73.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.62%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, PVLA will show a very strong growth in Earnings Per Share. The EPS will grow by 29.91% on average per year.
  • PVLA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 607.13% yearly.
EPS Next Y-17.14%
EPS Next 2Y-14.82%
EPS Next 3Y-22.99%
EPS Next 5Y29.91%
Revenue Next Year-100%
Revenue Next 2Y39.36%
Revenue Next 3Y871.72%
Revenue Next 5Y607.13%

3.3 Evolution

PVLA Yearly Revenue VS EstimatesPVLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
PVLA Yearly EPS VS EstimatesPVLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 20 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • PVLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year PVLA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PVLA Price Earnings VS Forward Price EarningsPVLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PVLA Per share dataPVLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • PVLA's earnings are expected to decrease with -22.99% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.82%
EPS Next 3Y-22.99%

More info and screens

0

5. Dividend

5.1 Amount

  • PVLA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PALVELLA THERAPEUTICS INC

NASDAQ:PVLA (2/3/2026, 8:00:02 PM)

After market: 79.91 0 (0%)

79.91

+0.01 (+0.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11
Earnings (Next)03-30
Inst Owners64.74%
Inst Owner Change3.71%
Ins Owners16.63%
Ins Owner Change0%
Market Cap946.13M
Revenue(TTM)N/A
Net Income(TTM)-34.73M
Analysts84.76
Price Target181.05 (126.57%)
Short Float %16.54%
Short Ratio4.87
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.13%
Min EPS beat(2)-20.45%
Max EPS beat(2)-13.81%
EPS beat(4)1
Avg EPS beat(4)-76.9%
Min EPS beat(4)-313.44%
Max EPS beat(4)40.1%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.43%
PT rev (3m)150%
EPS NQ rev (1m)-1.56%
EPS NQ rev (3m)-11.2%
EPS NY rev (1m)-0.48%
EPS NY rev (3m)-7.41%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 24.26
P/tB 24.26
EV/EBITDA N/A
EPS(TTM)-5.35
EYN/A
EPS(NY)-4.04
Fwd EYN/A
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-1.91
OCFYN/A
SpS0
BVpS3.29
TBVpS3.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -51.84%
ROE -89.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.21%
ROA(5y)-36.57%
ROE(3y)-79.28%
ROE(5y)-89.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.7
Quick Ratio 6.7
Altman-Z 17.32
F-Score3
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.62%
EPS Next Y-17.14%
EPS Next 2Y-14.82%
EPS Next 3Y-22.99%
EPS Next 5Y29.91%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y39.36%
Revenue Next 3Y871.72%
Revenue Next 5Y607.13%
EBIT growth 1Y-42.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-131.82%
EBIT Next 3Y-80.23%
EBIT Next 5Y50.12%
FCF growth 1Y52.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.85%
OCF growth 3YN/A
OCF growth 5YN/A

PALVELLA THERAPEUTICS INC / PVLA FAQ

What is the ChartMill fundamental rating of PALVELLA THERAPEUTICS INC (PVLA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PVLA.


What is the valuation status for PVLA stock?

ChartMill assigns a valuation rating of 0 / 10 to PALVELLA THERAPEUTICS INC (PVLA). This can be considered as Overvalued.


How profitable is PALVELLA THERAPEUTICS INC (PVLA) stock?

PALVELLA THERAPEUTICS INC (PVLA) has a profitability rating of 1 / 10.